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Background:  Valerian  root  and  lemon  balm  extracts  have  previously  shown  efﬁcacy  and  excellent  tol-
erability  in  children  < 12  years  suffering  from  restlessness  and  insomnia.  We  now examined  whether
treatment  with  a ﬁxed  combination  of both  may  also  improve  concentration,  hyperactivity  and  impul-
siveness.
Methods:  169  primary  school  children  suffering  from  hyperactivity  and concentration  difﬁculties  but
not  meeting  ADHS  criteria  were  treated  in an observational  study  by  27  ofﬁce  based  pediatricians  with
a  recommended  daily  dose  of  640 mg  valerian  root extract  WS® 1014  and  320  mg  lemon  balm  extract
WS® 1303  (Sandrin®), and evaluated  by  pediatricians  and  parents  using  standardized  questionnaires  at
baseline,  weeks  2 and  7.
Results:  The  fraction  of children  having  strong/very  strong  symptoms  of  poor  ability  to focus  decreased
from  75%  to  14%,  hyperactivity  from  61%  to  13%,  and  impulsiveness  from  59%  to 22%.  Parent  rated  social
behavior,  sleep  and  symptom  burden  showed  highly  signiﬁcant  improvements.  Only  in two  children  mild
transient  adverse  drug  reactions  were  observed.
Conclusion:  In primary  school  children  with  restlessness,  concentration  difﬁculties  and  impulsiveness
treatment  with  WS® 1014  and  WS® 1303  (Sandrin®) provides  a viable  option  in  addition  to counseling
and  education.
© 2014  Published  by Elsevier  GmbH.ntroduction
Attention deﬁcits, hyperactivity and impulsiveness in chil-
ren cause problems in families, school and other social relations
Storebø et al., 2011). In Germany, up to 700,000 children are
ffected by ADS/ADHS (Saß et al., 2003) and even more suffer from
ingle symptoms or symptom combinations of milder or ﬂuctuat-
ng intensity not fulﬁlling the criteria for ADHS diagnosis according
o DSM-IV or ICD-10. Consequently, prescription drugs are not indi-
ated, but parents suffer so much from this burden that they ask
or medical help (Gebhardt et al., 2008). Moreover, subthreshold
uvenile ADHS is a risk factor for addiction disorders and impaired
ocial interactions in adults (Shankman et al., 2009).
∗ Corresponding author. Tel.: +49 721 4005 332; fax: +49 7243 106 8573.
E-mail address: ute.paulsen@schwabe.de (U. Paulsen).
ttp://dx.doi.org/10.1016/j.phymed.2014.04.004
944-7113/© 2014 Published by Elsevier GmbH.Herbal medicines are frequently administered to children
because they are excellently tolerated and well accepted by parents
(Kraft, 2008; Larzelere et al., 2010). Valerian (Valeriana ofﬁci-
nalis L.) has been shown to improve sleep disturbances in adults
(Fernández-San-Martín et al., 2010; HMPC, 2007) and in chil-
dren (Francis and Dempster, 2002) when used as a monotherapy
or in combination with other herbal remedies. It has also been
suggested as medication for treatment of respiratory and car-
diovascular disease (Circosta et al., 2007): Lemon balm (Melissa
ofﬁcinalis L.) promotes relaxation and helps to get to sleep, and in
addition improves attention in young adults (Kennedy et al., 2002).
A combination of valerian and lemon balm extracts improved sleep
disturbances to a similar extent as did benzodiazepines but without
having their sedative side effects (Cerny and Schmid, 1999; Dreßing
et al., 1996). An observational study in 900 children reported good
results in the treatment of restlessness and sleep disturbances for
this combination (Müller and Klement, 2006).
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cig. 1. Chromatographic analysis of extracts used in the trial. (a) Chromatogram o
alerenic acid). (b) Chromatogram of lemon balm leaf extract; (analytical marker: r
We  therefore investigated the effects of a highly dosed prepa-
ation containing valerian and lemon balm on a wide range of
ymptoms and everyday life situation of children with hyperac-
ivity, attention and concentration deﬁcits but not fulﬁlling criteria
or ADHS diagnosis in a routine ofﬁce-based pediatric setting.
aterials and methods
ample preparation for extract analysis
The coated tablets of the herbal combination remedy (Sandrin®)
ontain 320 mg  of the quantiﬁed dry extract WS® 1014 from vale-
ian root (drug/extract ratio 3–6: 1, solvent ethanol 62% (m/m))
nd 160 mg  of the quantiﬁed lemon balm dry extract WS® 1303
drug/extract ratio 4–6: 1, solvent ethanol 30% (m/m)). These origi-
al tablets are used for chromatographic analysis (Fig. 1a) according
o the current version of the monographs for balm leaf extract
nd valerian extract in the Ofﬁcial European Pharmacopoeia (Ph.
ur.7.1/1898; Ph. Eur. 7.0/2524). Brieﬂy, to analyze valerian extract,
.2 g pulverized tablets were suspended in 25 ml  methanol, soni-
ated for 30 min  and ﬁltered using a 0.45 m ﬁlter.ian root extract (analytical marker: hydroxyvalerenic acid; acetoxyvalerenic acid;
inic acid).
To analyze lemon balm extract 145 mg  of pulverized tablets
were suspended in 50 ml  ethanol 60%, sonicated for 10 min and
centrifuged for 10 min  at 3590 × g. The supernatant was  used for
HPLC analysis.
HPLC analysis was  performed using Shimadzu LC 20 equipment.
To analyze valerian root extract, sesquiterpenic acids, calculated as
valerenic acid, were used as a marker. The assay was run using
an RP 18, e.g., Chromolith performance 100 mm  × 4.6 mm  column;
acetonitrile, 5 g/l solution of phosphoric acid (20:80 V/V) as eluent
A; 5 g/l solution of phosphoric acid, acetonitrile (20:80 V/V) as elu-
ent B. The gradient proﬁle was  0–1.25 min  60% A/40% B, 1.25–5 min
60% A/40% B to 20% A/80% B, ﬂow rate 2.0 ml/min. Absorption
was detected at 220 nm.  Calibration was performed by preparing
at least 3 reference solutions corresponding to different valerenic
acid concentrations (50–150 g/1 ml  in methanol), using valerian
standardized dry extract CRS.
To analyze lemon balm dry leaf extract, the extract was  applied
to an RP 18, e.g., Nucleosil 100, 5 m,  125 mm × 4 mm column. The
solvent was water: acetonitrile 2-propanol at a ratio of 100:27:3
(V/V/V) + 0.4% citric acid (m/V). The ﬂow rate was  1.0 ml/min.
Compounds were detected at 332 nm.  Calibration was performed
using rosmarinic acid dissolved in 60% ethanol, with at least 3
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ifferent concentrations within the approved range of linearity
4–120 g/ml rosmarinic acid, corresponding to approx. 0.7–20%
osmarinic acid, related to the original balm leaf extract). The
esults of representative HPLC analysis are displayed in Fig. 1b.
tudy design
This was a prospective, multi-center non-interventional study
ccording to §4 (3) sentence 3 of the German Medicine Act (AMG)
n 27 pediatric practices from all parts of Germany. Primary school
hildren suffering from hyperactivity and concentration difﬁcul-
ies but not meeting ADHS criteria according to DSM-IV or ICD-10
nd not taking stimulating drugs (methylphenidate) were included
nd treated as usual in the respective practices. They received 2 × 2
oated tablets of a herbal combination remedy (Sandrin®), the daily
osage containing 640 mg/d of the quantiﬁed dry extract WS® 1014
rom valerian root (drug/extract ratio 3–6:1, solvent ethanol 62%
m/m)) and 320 mg  of the quantiﬁed lemon balm dry extract WS®
303 (drug/extract ratio 4–6:1, solvent ethanol 30% (m/m)).
Patients having any of the contraindications listed in the prod-
ct information were excluded. The parents were informed about
ata protection and data handling and had to give their consent.
reatment period was 7 weeks with examinations at begin, after 2
eeks and at the end.
The attending pediatricians had to document demographic and
namnestic data, concomitant diseases and medications and con-
uct of the children at school, at home and in their leisure time.
he following symptoms were rated on Likert scales from 0 (not
resent) to 5 (very strong) with regard to the last 7 days: con-
entration problems, hyperactivity, impulsiveness, impaired social
ehavior, difﬁculties to fall asleep or to sleep night through,
nd morning fatigue. At the subsequent examinations symptoms,
hanges in therapy, compliance and adverse drug reactions were
ocumented and parents were asked for changes in the children’s
ehavior. They also had to ﬁll out a questionnaire on their chil-
ren’s behavior in the last 7 days at every visit. The questionnaire
omprised 18 questions with ﬁve-point Likert-scales on atten-
ion deﬁcits, nervousness, hyperactivity, impulsiveness, anxiety
nd behavior separately for school and familial environment, as
ell as three questions concerning the burden on the child and
n the family members caused by the symptoms. Statistical eval-
ation was descriptive and explorative. Descriptive p-values of
hanges were determined by Bowker’s Test on symmetry or by the
ilcoxon rank sum test. At the ﬁnal examination, pediatrician and
arents had to give a global assessment of efﬁcacy and tolerabil-
ty on four-point Likert-scales, each from their respective point of
iew. A possible correlation between efﬁcacy and compliance was
nalyzed by Fisher’s exact test. A sample size of 100 completely
valuable patients was intended to detect adverse drug effects of
5% incidence at least in one case.
esults
emographic data
From August 2011 to June 2012 evaluable data were obtained
rom 169 patients in 27 ofﬁces (1–30 patients per center), 152 were
ompletely documented. Mean age was 8.0 (6–11) years, mean
eight 131.7 cm and mean weight 30.1 kg. Two of three patients
ere male. The children attended class 1–6 of the elementary
chool.namnesis
At start, symptoms had existed since 24.3 months (1 month to 4
ears). 16.6% of the patients had been drug treated before, most ofe 21 (2014) 1098–1103
them with homeopathics, anthroposohics and omega-3 fatty acids.
Other preceding treatments were ergotherapy (14.8%), logopaedics
(4.7%) and behavioral therapy (3.0%). 24.3% of the patients suffered
from concomitant diseases like asthma (7.1%), atopic eczema (4.1%),
and dyslexia (2.4%). Accordingly, concomitant medication in alto-
gether 21 patients comprised glucocorticoids (8), -mimetics (5),
montelukast (4), and omega-3 fatty acids (2).
Compliance
In 96% of all cases the attending pediatricians administered
the recommended dosage of 2 × 2 coated tablets daily which was
exceeded (3 × 2) in only one case. Compliance was rated “very
good” or “good” by pediatricians in 74.9% of all cases, as “poor”
or “very bad” in 8.4%. Treatment was terminated prematurely in
16 patients, mainly because of insufﬁcient compliance (6), low efﬁ-
cacy (5), problems with intake (3) and/or other reasons (multiple
responses allowed). 77 patients terminated therapy after the ﬁnal
examination (29 because symptoms had improved or vanished, 29
because of insufﬁcient efﬁcacy, 10 for poor compliance), in 48 cases
continuation was recommended by the doctor.
Documentation by the pediatricians
At start, dominating symptoms were pronounced concentration
deﬁcits, hyperactivity and impulsiveness (mean indices 3.6–3.9),
followed by impaired social behavior (2.7); sleep disturbances and
morning fatigue were less prominent with indices of 1.9 and 2.5.
Under the herbal treatment all symptoms improved considerably
(p < 0.0001, Fig. 2). Initially, 37.6% of the children suffered always,
very often or often from difﬁculties to fall asleep, compared to only
9.1 at ﬁnal examination. Difﬁculties to sleep night through were
reduced from 19.4% to 6.1%.
Doctors reported substantial changes of the situation within
families: while 30.5% of the parents had not noticed any change, 45%
experienced reduced stress in everyday life, 30.2% more friendly
atmosphere and conversation, and in 13.6% of the families the fre-
quency of common activities had increased.
Documentation by the parents
At inclusion into the study, parents reported a high level of
distractibility and inattentiveness, followed by restlessness, hyper-
activity and impulsiveness. Moderate symptoms were poor staying
power and concentration ability, resistance to tasks requiring
persistence, difﬁculties to play quietly and concentrated, and for-
getfulness in everyday situations. Less pronounced symptoms
were nervousness, anxiety, aggressiveness, lack of self-control and
propensity for lying or cheating (Fig. 3).
“Pronounced distractibility” was the symptom with highest
index (4.15 on a scale from 1 to 5) at start of treatment, which
was reduced by 0.8 index points to 3.35 after 7 weeks; in contrast,
propensity for lying or cheating was  the least pronounced with 2.2
index points at start and 1.8 at ﬁnal examination. The mean index
of all questions was  3.2 at begin and declined to 2.7 during treat-
ment. There were no signiﬁcant differences reported for school and
family environment.
Parents regarded impairments in school as the most important
while problems with friends and in leisure time were less severe.
Burden on the families was perceived as higher than burden on
the children themselves. In all areas, similar improvements were
observed during the treatment period (Fig. 4, p < 0.0001, Bowker’s
test for symmetry). The percentage of parents perceiving their
child’s behavior as a heavy or very heavy burden on the family
decreased from 58% to 18%.
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oig. 2. Physicians’ ratings of symptoms at start of treatment, week 2 and week 7. In
hanges from week 0 to week 7 are signiﬁcant (p < 0.0001 for all symptoms, Bowke
reatment satisfaction
62% of the physicians and 58% of the parents rated efﬁcacy of
he preparation as “very good” or “good”, 9.9% of the physicians
nd 17.9% of the parents as “poor”, the rest rated “moderate”. The
octor’s judgment correlated very well with the reported compli-
nce (p = 0.001; Fisher’s exact test), while there was only a trend in
he parental judgment (p = 0.08).
afety and tolerability
Suspected adverse events were reported for two patients (1.18%;
5% CI 0.14–4.21%); in one case tiredness and irritability of mod-
rate degree increased which had existed already one week before
tart of treatment with Sandrin® and vanished two weeks after
edication was discontinued. These symptoms are often associ-
ted with restlessness and concentration problems so that a causal
elation with medication was judged “unlikely”.
ig. 3. Parents’ questionnaire on behavior and abilities of their child in family setting. Fiv
ain  score “deﬁnitely true” was rated 1 if questions referred to positive attributes (“able to
r  easily distractable”). p < 0.0001, Wilcoxon rank sum test for all questions except No. 16ore 1 = no symptoms, 5 = very severe, with regard to the last 7 days. ITT Population.
t of symmetry).
Another patient developed mild tics (eye blinking) for 4 days
after start of treatment which disappeared when medication with
Sandrin® was discontinued, and did not return after resumption.
Causal relation with the herbal preparation was  also regarded as
“unlikely” in this case.
Tolerability was classiﬁed as “very good” or “good” by 96.9% of
the pediatricians and 95.1% of the parents.
Discussion
Burden on relatives of restless and inattentive children is obvi-
ously high even when diagnostic criteria for ADHS are not fulﬁlled.
Problems arise where those children have to comply with duties
while social interactions in leisure and play are less affected. Treat-
ment with the herbal medication containing valerian and lemon
balm extracts reduced conﬂicts at school and in the families. This
increased the frequency of common activities within the families,
e-point Likert-scales from “deﬁnitely true” to “does not apply”. For calculation of a
 focus on given tasks”) and 5 when negative attributes were concerned (“inattentive
 (“.  . .delves into its occupation when busy”) and No. 9 (“. . .follows instructions”).
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Fig. 4. Burden on and impairment of child (patient) and its family in everyday life, at
school and at leisure. Index score 1 = does not apply; 5 = very severe. Changes from
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culties in children with intellectual deﬁcits: randomised trial. Phytomedicine 9,eek 0 to week 7 are signiﬁcant (p < 0.0001, Bowker’s test of symmetry).
hile an improvement of school grades was not (yet?) recognizable
uring the four months treatment time.
Our results tie in with earlier ﬁndings (Müller and Klement,
006) from an investigation on 918 children below 12 years of age
howing improvement of the main symptoms “restlessness” and
sleep disturbances” by at least 1–2 index points in 70.4% and 80.9%,
espectively. All other symptoms: physical weakness, rapid fatiga-
ility, hyperactivity, concentration deﬁcits, aggressiveness, loss of
ppetite, increased tiredness, listlessness and “other symptoms”
lso improved. Differences between children under 6 years and
chool children up to 12 years were not observed.
As early as 1984 an improvement of nervous disorders in
lderly people under treatment with valerian was demonstrated
Kamm-Kohl et al., 1984). In studies on adults with sleeping disor-
ers valerian or valerian combinations with other herbals proved
uperior to placebo (Donath et al., 2000; Dreßing et al., 1996;
ernández-San-Martín et al., 2010; Morin et al., 2005) and equiv-
lent to oxazepam (Ziegler et al., 2002). Statistically signiﬁcant
esults were only found after several weeks of treatment while
cute (Diaper and Hindmarch, 2004) or short time trials (Taibi et al.,
009) were not effective in sleep improvement. This means that
alerian needs sufﬁcient time to unfold its effects.
Lemon balm extract (600 mg)  improved mood, cognitive per-
ormance and attentiveness in young adults under mental stress
Kennedy et al., 2002, 2003, 2004) presumably via increasing
ctivity of acetylcholine. Essential oils (Chaiyana and Okonogi,
012) as well as constituents of the aqueous extract like cis-
nd trans-rosmarinic acid (Dastmalchi et al., 2009) inhibit acetyl-
holinesterase. Moreover, lemon balm extract binds to the nicotinic
nd muscarinic acetylcholine receptor (Wake et al., 2000) as was
lso demonstrated for human tissue (Kennedy et al., 2002, 2003).
There are indications that the effects of valerian arise from
nterplay of several constituents. Valerenic acid binds to 2- and
3-subunits of GABAA-receptors (Khom et al. 2007) which can
xplain anxiolytic, calming and mild anti-depressive properties of
he extract. In addition, effects of valerian on the 5-HT5A-receptor
re reported (Dietz et al. 2005) which has been suggested to be
nvolved in regulation of circadian rhythms (Thomas 2006).Efﬁcacy of herbal medicines strongly depends on the quality of
he speciﬁc extracts, i.e., on the concentration of effective ingre-
ients and a constant batch-to-batch composition. This suggestse 21 (2014) 1098–1103
use of clinically proven and registered products for therapeutic
purposes.
The product combining valerian and lemon balm extracts was
found effective and safe in the present study. Earlier investigations
showed that valerian, used in monotherapy or combination, did not
impair cognitive abilities and attentiveness while benzodiazepines
did so to a signiﬁcant degree, compared to placebo (Glass et al.,
2003; Hallam et al., 2003). Both of the herbal extracts improve sleep
quality on the long run but do not cause drowsiness and are there-
fore suitable for use in everyday life, as at school and at work. They
can be regarded as safe in usual recommended dosages. A clinical
pharmacology investigation in healthy volunteers did not ﬁnd clin-
ically signiﬁcant inﬂuences of valerian extract on CYP 450 enzymes
(Donovan et al., 2004).
In conclusion, primary school children with restlessness, con-
centration difﬁculties and impulsiveness but not fulﬁlling criteria
for ADHS diagnosis respond to 7 weeks treatment with WS® 1014
and WS® 1303 (Sandrin®) with a reduction of symptoms and of
problems in school and at home. Combined treatment with valerian
and lemon balm provides a viable option in addition to counseling
and education.
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